These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25050068)

  • 1. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation.
    Ieni A; Barresi V; Caltabiano R; Cascone AM; Del Sordo R; Cabibi D; Zeppa P; Lanzafame S; Sidoni A; Franco V; Tuccari G
    Onco Targets Ther; 2014; 7():1267-72. PubMed ID: 25050068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis.
    Ieni A; Barresi V; Caltabiano R; Caleo A; Bonetti LR; Lanzafame S; Zeppa P; Caruso RA; Tuccari G
    Int J Mol Sci; 2014 Dec; 15(12):22331-41. PubMed ID: 25479078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].
    Liu YY; Wu SF; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):393-6. PubMed ID: 27256047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Internodal HER2 heterogeneity of axillary lymph node metastases in breast cancer patients.
    Baroš IV; Tanasković N; Pellas U; Eri Ž; Tadić Latinović L; Tot T
    Bosn J Basic Med Sci; 2019 Aug; 19(3):242-248. PubMed ID: 30957723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
    Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.
    Yao ZX; Lu LJ; Wang RJ; Jin LB; Liu SC; Li HY; Ren GS; Wu KN; Wang DL; Kong LQ
    Med Oncol; 2014 Jan; 31(1):798. PubMed ID: 24307349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
    Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
    Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of using the cell block method to determine the discordance of the HR/HER2 expression in patients with metastatic breast cancer.
    Nakayama Y; Nakagomi H; Omori M; Inoue M; Takahashi K; Maruyama M; Takano A; Furuya K; Amemiya K; Ishii E; Oyama T
    Breast Cancer; 2016 Jul; 23(4):633-9. PubMed ID: 25968348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker heterogeneity between primary breast cancer and synchronous axillary lymph node metastases.
    Xi X; Huang XW; Yuan HZ; He C; Ni J; Yang FL
    Oncol Lett; 2020 Nov; 20(5):273. PubMed ID: 33014152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome.
    Satishkumar M; Ramesh M; Sanjive JG
    Indian J Surg Oncol; 2023 Mar; 14(1):72-80. PubMed ID: 36891419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer.
    Pellas U; Bauer A; Baroš IV; Fattorini C; Tot T
    Front Oncol; 2023; 13():1167567. PubMed ID: 37483511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis.
    Ba JL; Liu CG; Jin F
    Asian Pac J Cancer Prev; 2014; 15(21):9233-9. PubMed ID: 25422206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.
    Ataseven B; Gologan D; Gunesch A; Kehl V; Hoegel B; Beer M; Eiermann W
    Breast Care (Basel); 2012 Dec; 7(6):465-70. PubMed ID: 24715828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertumoral Heterogeneity of Primary Breast Tumors and Synchronous Axillary Lymph Node Metastases Reflected in IHC-Assessed Expression of Routine and Nonstandard Biomarkers.
    Kuncman W; Orzechowska M; Kuncman Ł; Kordek R; Taran K
    Front Oncol; 2021; 11():660318. PubMed ID: 34804912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
    Jensen JD; Knoop A; Ewertz M; Laenkholm AV
    Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between HER2, Estrogen Receptors and Progesterone Receptors in Primary Breast Carcinomas and Matched Lymph Node Metastases.
    Desouki MM; Atta IS; Wolff DJ; Self SE
    Turk Patoloji Derg; 2016; 32(3):178-85. PubMed ID: 27562392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.